Q: What is Jakafi used for?

Jakafi is used to treat: myelofibrosis polycythemia vera graft-versus-host disease

Q: How does Jakafi work?

Mechanism of Action Jakafi belongs to a class of medications known as kinase inhibitors. It works by blocking the activity of enzymes called Janus Associated Kinases, specifically JAK1 and JAK2. These enzymes play a critical role in the signaling pathways that tell the body how to produce blood cells and how the immune system should respond to various triggers. Managing Blood Disorders In certain blood and bone marrow disorders, such as myelofibrosis and polycythemia vera, the JAK signaling pathway becomes overactive. This overactivity causes the body to produce too many blood cells and leads to significant inflammation. By inhibiting JAK1 and JAK2, Jakafi helps to: Slow down the excessive production of blood cells. Reduce inflammation throughout the body. Shrink an enlarged spleen, which is a common symptom of these conditions. Role in Graft-Versus-Host Disease For patients with graft-versus-host disease (GVHD), Jakafi works by interfering with the signals that cause transplanted immune cells to attack the patient's own tissues. By blocking these pathways, the medication helps dampen the immune response and reduce the damage caused by the condition.

Q: What are the active ingredients in Jakafi?

The active ingredient in Jakafi is ruxolitinib .

Q: What are the side effects of Jakafi?

Common side effects of Jakafi may include: Anemia Thrombocytopenia Bruising and others. Always consult with a healthcare professional about potential side effects.

Q: What drug class is Jakafi?

Jakafi belongs to the JAK1/JAK2 inhibitor drug class.

Q: What is the dosage of Jakafi and how do I take it?

General Administration Jakafi is taken by mouth, usually twice daily. It can be taken with or without food. It is important to take the medication at the same times each day to maintain a consistent level in your body. How to Use Swallow tablets whole. Do not crush, break, or chew the tablets. For patients with a nasogastric tube, the tablets can be suspended in water and administered through the tube as directed by a healthcare professional. Missed Dose If you miss a dose, skip the missed dose and take your next dose at your regular scheduled time. Do not take extra medicine or two doses at once to make up for a missed dose. Monitoring and Adjustments A healthcare provider will monitor your blood counts regularly through blood tests. These results are used to determine the correct dose for your specific needs. Do not stop taking Jakafi or change your dose without talking to your doctor, as stopping the medication abruptly can cause your condition to worsen.

Q: Is Jakafi safe during pregnancy and breastfeeding?

Pregnancy There is limited research on the use of Jakafi in pregnant individuals. In animal studies, the medication was associated with an increased risk of pregnancy loss and lower birth weights in offspring. Because of these potential risks, healthcare providers typically only prescribe Jakafi during pregnancy if the benefits to the patient outweigh the risks to the fetus. If you are pregnant or planning to become pregnant, it is important to discuss your treatment options with your doctor. Individuals who can become pregnant may be advised to use effective contraception during treatment. Breastfeeding It is currently unknown whether Jakafi passes into human breast milk. Due to the potential for serious adverse reactions in a nursing infant, breastfeeding is not recommended while taking this medication. Most guidelines suggest waiting at least two weeks after the final dose of Jakafi before breastfeeding.

Q: What forms and strengths does Jakafi come in?

Dosage Forms Jakafi is available as a tablet for oral administration. Oral tablet

Q: What is the FDA approval status of Jakafi?

FDA Approval and Indications Jakafi was first approved by the U.S. Food and Drug Administration (FDA) in 2011. It is currently indicated for the treatment of: Intermediate or high-risk myelofibrosis, including primary myelofibrosis and myelofibrosis that follows other blood conditions. Polycythemia vera in adults who have had an inadequate response to or cannot tolerate hydroxyurea. Steroid-refractory acute graft-versus-host disease (GVHD) in adult and pediatric patients 12 years and older. Chronic graft-versus-host disease in adult and pediatric patients 12 years and older after the failure of one or two previous systemic treatments. Regulatory Safety Status In 2021, the FDA issued a safety communication requiring new and updated warnings for certain Janus kinase (JAK) inhibitors regarding increased risks of serious heart-related events, cancer, blood clots, and death. However, the FDA explicitly stated that Jakafi was not included in this specific safety communication because it is not indicated for the treatment of inflammatory conditions like rheumatoid arthritis. While Jakafi does not carry the same boxed warnings as some other JAK inhibitors, the FDA-approved labeling requires healthcare providers to monitor patients for other serious risks, including: Serious bacterial, mycobacterial, fungal, and viral infections. Changes in blood counts, such as anemia, thrombocytopenia, and neutropenia. Non-melanoma skin cancers. Increased lipid levels (cholesterol). There is currently no Risk Evaluation and Mitigation Strategy (REMS) required for the distribution or use of Jakafi.

Question 1

What is Jakafi?

Accepted Answer

Jakafi is a targeted therapy that works by interfering with specific enzymes in the body called Janus kinases. These enzymes play a key role in the signaling pathways that control the production of blood cells and the activity of the immune system.

By blocking these enzymes, the medication helps manage the underlying processes of certain chronic conditions. It is designed to target overactive signaling that can lead to abnormal cell growth or inflammation.

Question 2

What is Jakafi used for?

Accepted Answer

Jakafi is used to treat:

myelofibrosis
polycythemia vera
graft-versus-host disease

Question 3

How does Jakafi work?

Accepted Answer

Mechanism of Action

Jakafi belongs to a class of medications known as kinase inhibitors. It works by blocking the activity of enzymes called Janus Associated Kinases, specifically JAK1 and JAK2. These enzymes play a critical role in the signaling pathways that tell the body how to produce blood cells and how the immune system should respond to various triggers.

Managing Blood Disorders

In certain blood and bone marrow disorders, such as myelofibrosis and polycythemia vera, the JAK signaling pathway becomes overactive. This overactivity causes the body to produce too many blood cells and leads to significant inflammation. By inhibiting JAK1 and JAK2, Jakafi helps to:

Slow down the excessive production of blood cells.
Reduce inflammation throughout the body.
Shrink an enlarged spleen, which is a common symptom of these conditions.

Role in Graft-Versus-Host Disease

For patients with graft-versus-host disease (GVHD), Jakafi works by interfering with the signals that cause transplanted immune cells to attack the patient's own tissues. By blocking these pathways, the medication helps dampen the immune response and reduce the damage caused by the condition.

Question 4

What are the active ingredients in Jakafi?

Accepted Answer

The active ingredient in Jakafi is ruxolitinib.

Question 5

What are the side effects of Jakafi?

Accepted Answer

Common side effects of Jakafi may include:

Anemia
Thrombocytopenia
Bruising
and others.

Always consult with a healthcare professional about potential side effects.

Question 6

What drug class is Jakafi?

Accepted Answer

Jakafi belongs to the JAK1/JAK2 inhibitor drug class.

Question 7

What is the dosage of Jakafi and how do I take it?

Accepted Answer

General Administration

Jakafi is taken by mouth, usually twice daily. It can be taken with or without food. It is important to take the medication at the same times each day to maintain a consistent level in your body.

How to Use

Swallow tablets whole. Do not crush, break, or chew the tablets.
For patients with a nasogastric tube, the tablets can be suspended in water and administered through the tube as directed by a healthcare professional.

Missed Dose

If you miss a dose, skip the missed dose and take your next dose at your regular scheduled time. Do not take extra medicine or two doses at once to make up for a missed dose.

Monitoring and Adjustments

A healthcare provider will monitor your blood counts regularly through blood tests. These results are used to determine the correct dose for your specific needs. Do not stop taking Jakafi or change your dose without talking to your doctor, as stopping the medication abruptly can cause your condition to worsen.

Question 8

Is Jakafi safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

There is limited research on the use of Jakafi in pregnant individuals. In animal studies, the medication was associated with an increased risk of pregnancy loss and lower birth weights in offspring. Because of these potential risks, healthcare providers typically only prescribe Jakafi during pregnancy if the benefits to the patient outweigh the risks to the fetus.

If you are pregnant or planning to become pregnant, it is important to discuss your treatment options with your doctor. Individuals who can become pregnant may be advised to use effective contraception during treatment.

Breastfeeding

It is currently unknown whether Jakafi passes into human breast milk. Due to the potential for serious adverse reactions in a nursing infant, breastfeeding is not recommended while taking this medication. Most guidelines suggest waiting at least two weeks after the final dose of Jakafi before breastfeeding.

Question 9

What forms and strengths does Jakafi come in?

Accepted Answer

Dosage Forms

Jakafi is available as a tablet for oral administration.

Oral tablet

Question 10

What is the FDA approval status of Jakafi?

Accepted Answer

FDA Approval and Indications

Jakafi was first approved by the U.S. Food and Drug Administration (FDA) in 2011. It is currently indicated for the treatment of:

Intermediate or high-risk myelofibrosis, including primary myelofibrosis and myelofibrosis that follows other blood conditions.
Polycythemia vera in adults who have had an inadequate response to or cannot tolerate hydroxyurea.
Steroid-refractory acute graft-versus-host disease (GVHD) in adult and pediatric patients 12 years and older.
Chronic graft-versus-host disease in adult and pediatric patients 12 years and older after the failure of one or two previous systemic treatments.

Regulatory Safety Status

In 2021, the FDA issued a safety communication requiring new and updated warnings for certain Janus kinase (JAK) inhibitors regarding increased risks of serious heart-related events, cancer, blood clots, and death. However, the FDA explicitly stated that Jakafi was not included in this specific safety communication because it is not indicated for the treatment of inflammatory conditions like rheumatoid arthritis.

While Jakafi does not carry the same boxed warnings as some other JAK inhibitors, the FDA-approved labeling requires healthcare providers to monitor patients for other serious risks, including:

Serious bacterial, mycobacterial, fungal, and viral infections.
Changes in blood counts, such as anemia, thrombocytopenia, and neutropenia.
Non-melanoma skin cancers.
Increased lipid levels (cholesterol).

There is currently no Risk Evaluation and Mitigation Strategy (REMS) required for the distribution or use of Jakafi.

Question 11

What should I know about Jakafi and cost?

Accepted Answer

Factors Affecting Cost

The cost of Jakafi can vary based on several factors, including the specific condition being treated, the prescribed dosage, and the pharmacy used. Because it is a specialized treatment, it is typically more expensive than common medications.

Insurance and Prior Authorization

Most private insurance plans and Medicare Part D cover Jakafi, but they often require prior authorization. This process involves your healthcare provider submitting documentation to the insurance company to confirm the medication is medically necessary before coverage is approved. Your out-of-pocket costs, such as copays or coinsurance, will depend on your specific plan's formulary and deductible status.

Generic Availability

There is currently no generic version of Jakafi (ruxolitinib) available. Brand-name medications without generic alternatives generally have higher costs until patent protections expire and generic manufacturers can enter the market.

Financial Assistance Programs

The manufacturer of Jakafi offers support programs to help patients manage the cost of the drug. These may include:

Copay Cards: These can reduce out-of-pocket expenses for patients with commercial (private) insurance.
Patient Assistance Programs: These programs may provide the medication at no cost or a reduced cost for individuals who are uninsured or underinsured and meet specific income requirements.

Specialty Pharmacies

Jakafi is usually distributed through specialty pharmacies rather than standard retail pharmacies. These pharmacies are equipped to handle high-cost medications that require special handling, monitoring, or patient support services. Your insurance provider or doctor can help identify which specialty pharmacy you must use.

Jakafi

📋Overview

How It Works

Uses

Active Ingredients

Common Side Effects

Warnings & Precautions

Dosage

Pregnancy & Breastfeeding

Frequently Asked Questions

📚References

Found an Error?

Find Discounts for Jakafi

Hospitals.net Disclosure